PT - JOURNAL ARTICLE AU - Langley, Jason AU - Hwang, Kristy S. AU - Hu, Xiaoping P. AU - Huddleston, Daniel E. TI - Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit AID - 10.1101/2022.10.26.22281257 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.26.22281257 4099 - http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257.short 4100 - http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257.full AB - Introduction Striatal dopamine transporter imaging using 123I-ioflupane SPECT (DaTScan, GE) identifies 5-20% of newly diagnosed Parkinson’s disease (PD) subjects enrolling in clinical studies to have scans without evidence of dopaminergic deficit (SWEDD). These individuals meet diagnostic criteria for PD, but do not clinically progress as expected, and they are not believed to have neurodegenerative parkinsonism. Inclusion of SWEDD participants in PD biomarker studies or therapeutic trials may therefore cause them to fail. DaTScan can identify SWEDD individuals, but it is expensive and not widely available; an alternative imaging approach is needed. Here, we evaluate the use of neuromelanin-sensitive, iron-sensitive, and diffusion contrasts in substantia nigra pars compacta (SNpc) to differentiate SWEDD from PD individuals.Methods Neuromelanin-sensitive, iron-sensitive, and diffusion imaging data for SWEDD, PD, and control subjects were downloaded from the Parkinson’s Progression Markers Initiative (PPMI) database. SNpc volume, SNpc iron (R2), and SNpc free water (FW) were measured for each participant.Results Significantly smaller SNpc volume was seen in PD as compared to SWEDD (P<10−3) and control (P<10−3) subjects. SNpc FW was elevated in the PD group relative to controls (P=0.017). No group difference was observed in SNpc R2.Conclusion In conclusion, nigral volume and FW in the SWEDD group were similar to that of controls, while a reduction in nigral volume and increased FW were observed in the PD group relative to SWEDD and control participants. These results suggest that these MRI measures should be explored as a cost-effective alternative to DaTScan for evaluation of the nigrostriatal system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the NIH-NINDS 1K23NS105944-01A1 (Huddleston), NIH-NIA 1U19AG071754-01 (Huddleston, Hu, Langley), the Department of Veteran Affairs 1I01RX002967-01A2 (Huddleston), the Emory American Parkinson's Disease Association Center for Advanced Research (Huddleston), the Emory Lewy Body Dementia Association Research Center of Excellence (Huddleston), the Michael J Fox Foundation (MJF-10854, MJFF-010556; Huddleston, Hu, Langley).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used ONLY openly available human data that were originally located at: www.ppmi-info.org/dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data supporting these analyses are available through the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data).